Recently, Li and colleagues [32] proposed that AP-2α overexpression in breast cancer cells is the consequence of a stabilization of the protein resulting from a defective proteasomal degradation, leading to an increased ERBB2 gene expression. This evidence concerns the gene ERBB2 and breast carcinoma.